People with sickle cell disease (SCD) seeking emergency care for vaso-occlusive crises (VOCs) are often not triaged appropriately,…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Mortality rates related to sickle cell disease (SCD) have increased in the U.S. in recent decades, while mortality for…
Scientists at New York University (NYU) are teaming up with Nigerian-born music artist Adekunle Gold on a project to improve…
Young people with sickle cell disease (SCD) who live in areas with more air pollution are more likely to…
People with severe sickle cell disease (SCD) have reported significant improvements in their quality of life after receiving the…
Correctsequence Therapeutics’ experimental gene-editing therapy CS-101 has been used to treat a person with sickle cell disease (SCD) for…
People with sickle cell disease (SCD) may have a higher risk of developing blood cancer, but a lower risk…
BEAM-101, a genetically modified cell therapy for sickle cell disease (SCD) that’s being tested in clinical trials, has been…
An algorithm that grew out of a collaboration between different specialties at the Medical University of South Carolina (MUSC) may…
Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of Lyfgenia (lovotibeglogene autotemcel), Bluebird’s gene therapy…